Tempus AI responded that the report was "riddled with hypotheticals and inaccuracies and fails to address Tempus’ history of ...

In an exciting development for Tempus AI (NasdaqGS:TEM), the company experienced a significant 51% increase in its share price over the last quarter. This surge coincides with major events including ...

TEM expands major partnerships with AZN, ILMN, and PSNL, fueling AI-driven R&D and widening its precision medicine reach.

Tempus AI Inc. misled investors about the worth of its deals and artificial intelligence abilities, obscuring weaknesses with ...

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Tempus AI, Inc. ("Tempus" or "the Company") (NASDAQ: TEM) for violations of §§10 ...

Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a ...